You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
A consortium led by the Barcelona-based company recently received €150,000 in EU funding to bring the platform to market.
The effort, called INNO4COV-19, was awarded €6.1 million last month to support the commercialization of new diagnostics.
The effort is one of 23 research projects selected as part of a new, €128 million EU package to combat COVID-19.
Blueprint Genetics, recently acquired by Quest Diagnostics in January, will base the 600-gene panel on its whole-exome sequencing capability.
While results are preliminary, the test could potentially be used in lieu of a liver biopsy.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.
While the first task of the centers will be to digitize their workflows to improve efficiency, they also aim to eventually develop new AI-based analytical tools for diagnosing patients.
The system relies on the use of scannable safety code cards containing patient data, along with a web portal and automated analysis tools that deliver customized diagnostic reports.
According to project organizers, feasibility testing in the first phase of the project was successful and clinical trials are planned for later this year.